Form 4 · Filed Jun 11, 2026, 08:26 PM UTC
KALV/KalVista Pharmaceuticals, Inc.
Yea Christopher — CHIEF DEVELOPMENT OFFICER
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
11 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | D | other | 229,918 | $0 | — | 0 |
| Jun 11, 2026 | D | other | 53,500 | — | — | 0 |
| Jun 11, 2026 | D | other | 52,600 | — | — | 0 |
| Jun 11, 2026 | D | other | 27,900 | — | — | 0 |
| Jun 11, 2026 | D | other | 60,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 31,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 20,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 18,920 | — | — | 0 |
| Jun 11, 2026 | D | other | 80,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 25,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 41,250 | — | — | 0 |
Source: SEC EDGAR raw filing ↗ · Accession 0001691102-26-000009